Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 2/2020

01.02.2020 | Original Article – Clinical Oncology

Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer

verfasst von: Se Young Choi, Byung Hoon Chi, Bumjin Lim, Yoon Soo Kyung, Dalsan You, In Gab Jeong, Cheryn Song, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Here, we re-checked the American Joint Committee on Cancer 7th edition subclassification and confirmed the possibility of percent tumor volume as a prognostic factor for biochemical recurrence in the 8th edition subclassification.

Methods

A total of 1073 patients with pathologic T2 stage disease who underwent radical prostatectomy were included. Exclusion criteria were neoadjuvant therapy and pathologic T3 and N1 disease. Biochemical recurrence-free survival was estimated using the Kaplan–Meier method. Cox hazard regression was used to predict biochemical recurrence.

Results

According to the 7th edition subclassification, 141 patients (13.1%) had T2a, 43 (4.0%) had T2b, and 889 (82.9%) had T2c disease. The 7th edition subclassification did not differ significantly on Kaplan–Meier analysis (p = 0.502). Mean percent tumor volume was 8.7 ± 8.0% (interquartile range, 5–10%). Percent tumor volume was positively correlated with initial prostate-specific antigen, grade group, surgical margin, and T2 subclassification (all p < 0.001). The 7th edition subclassification was not a significant factor, whereas percent tumor volume was (hazard ratio, 1.023; 95% confidence interval, 1.005–1.041; p = 0.0128) on multivariate analysis. On Kaplan–Meier analysis, percent tumor volume (> 7.5% vs ≤ 7.5%) differed significantly for biochemical recurrence-free survival (p < 0.001).

Conclusions

The 7th edition pathologic T2 subclassification had poor prognostic value for biochemical recurrence in our cohort. Elimination of the 8th edition subclassification was suitable. Percent tumor volume classified biochemical recurrence prognosis in pathologic T2 stage. Therefore, percent tumor volume can be a candidate factor for the next T2 subclassification.
Literatur
Zurück zum Zitat American College of Surgeons (2017) AJCC cancer staging handbook: from the AJCC cancer staging manual, 7th edn. Springer, New York American College of Surgeons (2017) AJCC cancer staging handbook: from the AJCC cancer staging manual, 7th edn. Springer, New York
Zurück zum Zitat Cheng L et al (1998) Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 90:233–237CrossRefPubMed Cheng L et al (1998) Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 90:233–237CrossRefPubMed
Zurück zum Zitat Fehrenbacher L, Capra AM, Quesenberry CP Jr, Fulton R, Shiraz P, Habel LA (2014) Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol 32:2151–2158. https://doi.org/10.1200/JCO.2013.52.0858 CrossRefPubMed Fehrenbacher L, Capra AM, Quesenberry CP Jr, Fulton R, Shiraz P, Habel LA (2014) Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol 32:2151–2158. https://​doi.​org/​10.​1200/​JCO.​2013.​52.​0858 CrossRefPubMed
Zurück zum Zitat Humphrey PA, Vollmer RT (1997) Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 10:326–333PubMed Humphrey PA, Vollmer RT (1997) Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. Mod Pathol 10:326–333PubMed
Zurück zum Zitat Meng Y, Li H, Xu P, Wang J (2015) Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy: a meta-analysis. Int J Clin Exp Med 8:22319–22327PubMedPubMedCentral Meng Y, Li H, Xu P, Wang J (2015) Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy: a meta-analysis. Int J Clin Exp Med 8:22319–22327PubMedPubMedCentral
Zurück zum Zitat Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT (1995) Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154:1818–1824CrossRefPubMed Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT (1995) Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154:1818–1824CrossRefPubMed
Zurück zum Zitat Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395–1400CrossRefPubMed Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395–1400CrossRefPubMed
Zurück zum Zitat Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM (2002) Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 167:103–111CrossRefPubMed Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM (2002) Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 167:103–111CrossRefPubMed
Metadaten
Titel
Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer
verfasst von
Se Young Choi
Byung Hoon Chi
Bumjin Lim
Yoon Soo Kyung
Dalsan You
In Gab Jeong
Cheryn Song
Jun Hyuk Hong
Hanjong Ahn
Choung-Soo Kim
Publikationsdatum
01.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-019-03085-w

Weitere Artikel der Ausgabe 2/2020

Journal of Cancer Research and Clinical Oncology 2/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.